Skip to content

Evaluation of Serum Levels of Interlukin-15 and Interlukin-21 in Patients With Alopecia Areata

Evaluation of Serum Levels of Interlukin-15 and Interlukin-21 in Patients With Alopecia Areata

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05910138
Enrollment
90
Registered
2023-06-18
Start date
2023-07-01
Completion date
2024-07-01
Last updated
2023-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia Areata

Brief summary

Alopecia areata (AA) is a type of non-cicatricial alopecia. The most common presentation of AA is localized patches of hair loss on the scalp. The extensive forms of AA presented as diffuse hair loss of the scalp (alopecia totalis) and diffuse hair loss through the entire body including the eyelashes and eyebrows (alopecia universalis). AA affects approximately 2% of the general population. AA occurs at any age. The peak of incidence is higher in the second and third decades of life. AA may be associated with several autoimmune diseases including thyroid diseases, lupus erythematosus, vitiligo, psoriasis, rheumatoid arthritis and inflammatory bowel disease. The frequency of the disease varies between geographically separate populations. These diseases associations suggest a relationship between AA and autoimmunity. Human hair has an important cosmetic and communicational role. We may find significant psychological distress in persons with partial and complete hair loss. AA is associated with psychiatric morbidity especially anxiety and depression. The pathogenesis of AA involves a complex interaction between genetic, environmental and immune factors. The histopathology of the disease differs according to the stage of the disease. In the acute stage of AA, there is a dense accumulation of lymphocytes (CD4 &CD8) around hair bulbs so called swarm of bees. In chronic stage, the inflammation may or may not resolve, but there is increase in number of catagen and, or telogen hair and pigmentary incontinence. In the recovery stage, there is minimal inflammation and increase in anagen hair. T-helper17 cells are unique subset of T-helper cells which produce many interleukins (IL) e.g. IL-17A, IL-17F, IL-21, IL-22, IL-6 and tumor necrosis factor (TNF). The maturation of Th-17 needs the stimulation of naïve T cells by both TGF and IL-21. IL-21 is a cytokine that is produced mostly by activated CD4 T cells. It controls the differentiation and activity of T cells, B cells and NK cells. IL-21 could be a promising marker in the diagnosis of AA and also can be used as a marker of its activity. IL-15 is a pleotropic cytokine that has multiple effects on different body cell types. It affects the function of cells of both innate and adaptive immune system. IL-15 is well known to promote lymphocytic development and suggested to play a role in some autoimmune diseases e.g. multiple sclerosis, rheumatoid arthritis, ulcerative colitis and celiac disease. IL-15 inhibits the well-known self-tolerance that mediated by activation - induced cell death, promotes maintenance of CD8+ memory T cells with induction of some cytokines which involved in autoimmune process e.g. TNF- and IL-1B. IL-15 is positively correlated with the number and the extent of AA so it could be a possible marker of AA severity.

Interventions

DIAGNOSTIC_TESTSerum Interlukin-15

Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.

DIAGNOSTIC_TESTSerum Interlukin-21

Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients of both sex with active and stable AA.

Exclusion criteria

* -Pregnant patients. * Lactating patients. * Patients with other differential diagnoses of AA (Trichotillomania, temporal triangular alopecia, and tinea capitis).

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of Serum levels of Interlukin-1512 monthsDetection of its relation to activity and severity of Alopecia Areata
Evaluation of Serum levels of Interlukin-2112 monthsDetection of its relation to activity and severity of Alopecia Areata

Countries

Egypt

Contacts

Primary ContactMarina S George, Resident
marian_goarge@med.sohag.edu.eg01273016740
Backup ContactHanan A Metwally, Professor
01118872013

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026